Susan L Dalrymple
Overview
Explore the profile of Susan L Dalrymple including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar R, Jonnatan S, Sanin D, Vakkala V, Kadam A, Kumar S, et al.
medRxiv
. 2024 Dec;
PMID: 39711733
Supraphysiological androgen (SPA) treatment can paradoxically restrict growth of castration-resistant prostate cancer with high androgen receptor (AR) activity, which is the basis for use of Bipolar Androgen Therapy (BAT) for...
2.
Nouri M, Varkaris A, Ridinger M, Dalrymple S, Dennehy C, Isaacs J, et al.
Mol Cancer Ther
. 2024 Jun;
23(10):1404-1417.
PMID: 38894678
Polo-like kinase 1 (PLK1) inhibitors have had limited antitumor efficacy as single agents, and focus of current efforts is on combination therapies. We initially confirmed that the PLK1-specific inhibitor onvansertib...
3.
Jasmine S, Mandl A, Krueger T, Dalrymple S, Antony L, Dias J, et al.
Prostate
. 2024 Apr;
84(10):909-921.
PMID: 38619005
Introduction: Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive...
4.
Isaacs J, Dalrymple S, Antony L, Marc Rosen D, Coleman I, Nelson P, et al.
Prostate
. 2023 Aug;
83(15):1470-1493.
PMID: 37559436
Background: The quinoline-3-carboxamide, Tasquinimod (TasQ), is orally active as a maintenance therapy with an on-target mechanism-of-action via allosteric binding to HDAC4. This prevents formation of the HDAC4/NCoR1/HDAC3 complex, disrupting HIF-1α...
5.
Sena L, Kumar R, Sanin D, Thompson E, Rosen D, Dalrymple S, et al.
J Clin Invest
. 2022 Oct;
132(23).
PMID: 36194476
Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological...
6.
Zhu Y, Dalrymple S, Coleman I, Zheng S, Xu J, Hooper J, et al.
Oncogene
. 2021 May;
40(22):3914-3916.
PMID: 33958727
No abstract available.
7.
Brennen W, Zhu Y, Coleman I, Dalrymple S, Antony L, Patel R, et al.
JCI Insight
. 2021 Mar;
6(8).
PMID: 33724955
Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with the emergence of AR- neuroendocrine prostate cancer (NEPC) coupled with mutations/deletions in PTEN,...
8.
Zhu Y, Dalrymple S, Coleman I, Zheng S, Xu J, Hooper J, et al.
Oncogene
. 2021 Feb;
40(11):2148.
PMID: 33564077
No abstract available.
9.
Zhu Y, Dalrymple S, Coleman I, Zheng S, Xu J, Hooper J, et al.
Oncogene
. 2020 Sep;
39(45):6935-6949.
PMID: 32989253
The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors...
10.
Rogers O, Antony L, Levy O, Joshi N, Simons B, Dalrymple S, et al.
Mol Cancer Ther
. 2020 Sep;
19(11):2353-2362.
PMID: 32943549
PRX302 is a highly potent, mutant bacterial pore-forming biologic protoxin engineered for selective activation by PSA, a serine protease expressed by benign and malignant prostate epithelial cells. Although being developed...